Latest from Mayo Clinic Cancer Center

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer.
 
The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone extended overall survival for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidomide and dexamethasone alone.
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the quality of life findings for a dose-escalation study of regorafenib (Stivarga) in metastatic colorectal cancer.
 
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses genetic abnormalities in multiple myeloma.
 
Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.
Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD. 
Mark J. Truty, MD, MS, assistant professor of surgery, Mayo Clinic, discusses challenges with treating patients with pancreatic cancer.
Patients with peripheral T-cell lymphoma are more likely to have superior overall survival if they have previously demonstrated event-free survival at 24 months.
Publication Bottom Border
Border Publication
x